Literature DB >> 11559474

An overview of psychiatric symptoms in Huntington's disease.

K E Anderson1, K S Marder.   

Abstract

Huntington's disease (HD) is an inherited autosomal dominant disorder characterized by neurologic, cognitive, and psychiatric symptomatology. Psychiatric symptoms in HD are often amenable to treatment, and relief of these symptoms may provide significant improvement in quality of life. This review will briefly describe neurologic, neuropsychologic and brain imaging data, and then review psychiatric syndromes seen in HD and their treatment.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11559474     DOI： 10.1007/s11920-996-0030-2

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


  94 in total

Review 1.  Huntington's disease and its association with psychopathology.

Authors:  N De Marchi; R Mennella
Journal:  Harv Rev Psychiatry       Date:  2000 Jan-Feb       Impact factor: 3.732

2.  Acquired obsessive-compulsive disorder associated with basal ganglia lesions.

Authors:  R C Chacko; M A Corbin; R G Harper
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

3.  Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification.

Authors:  D López-Villegas; J Kulisevsky; J Deus; C Junqué; J Pujol; E Guardia; J M Grau
Journal:  Arch Neurol       Date:  1996-03

4.  Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.

Authors:  B Kremer; C M Clark; E W Almqvist; L A Raymond; P Graf; C Jacova; M Mezei; M A Hardy; B Snow; W Martin; M R Hayden
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.

Authors:  P G Como; A J Rubin; C F O'Brien; K Lawler; C Hickey; A E Rubin; R Henderson; M P McDermott; M McDermott; K Steinberg; I Shoulson
Journal:  Mov Disord       Date:  1997-05       Impact factor: 10.338

6.  A double blind trial of lithium carbonate and haloperidol in Huntington's chorea.

Authors:  D P Leonard; M A Kidson; J G Brown; P J Shannon; S Taryan
Journal:  Aust N Z J Psychiatry       Date:  1975-06       Impact factor: 5.744

7.  Suicide risk in Huntington's disease.

Authors:  L Di Maio; F Squitieri; G Napolitano; G Campanella; J A Trofatter; P M Conneally
Journal:  J Med Genet       Date:  1993-04       Impact factor: 6.318

8.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.

Authors:  G J Harris; G D Pearlson; C E Peyser; E H Aylward; J Roberts; P E Barta; G A Chase; S E Folstein
Journal:  Ann Neurol       Date:  1992-01       Impact factor: 10.422

9.  Development of neuropsychological deficits in Huntington's disease.

Authors:  R C Josiassen; L M Curry; E L Mancall
Journal:  Arch Neurol       Date:  1983-12

10.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422
View more
  15 in total

1.  Extrastriatal dopamine D(2) receptor binding in Huntington's disease.

Authors:  Mouna Esmaeilzadeh; Lars Farde; Per Karlsson; Andrea Varrone; Christer Halldin; Susanna Waters; Joakim Tedroff
Journal:  Hum Brain Mapp       Date:  2010-09-30       Impact factor: 5.038

2.  Psychiatric disorders, spinocerebellar ataxia type 3 and CAG expansion.

Authors:  Uanda Cristina Almeida Silva; Wilson Marques; Charles Marques Lourenço; Jaime Eduardo C Hallak; Flávia L Osório
Journal:  J Neurol       Date:  2015-06-13       Impact factor: 4.849

3.  A pilot study of the prevalence of psychiatric disorders in PLS and ALS.

Authors:  Edward D Huey; Jeremy Koppel; Nicole Armstrong; Jordan Grafman; Mary Kay Floeter
Journal:  Amyotroph Lateral Scler       Date:  2010-05-03

4.  Obsessive and compulsive symptoms in prediagnosed Huntington's disease.

Authors:  Leigh J Beglinger; Jane S Paulsen; David B Watson; Chiachi Wang; Kevin Duff; Douglas R Langbehn; David J Moser; Henry L Paulson; Elizabeth H Aylward; Noelle E Carlozzi; Sarah Queller; Julie C Stout
Journal:  J Clin Psychiatry       Date:  2008-09-09       Impact factor: 4.384

5.  Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.

Authors:  Brett D Dufour; Jodi L McBride
Journal:  Neurobiol Dis       Date:  2018-10-05       Impact factor: 5.996

Review 6.  Neuroprotection for Huntington's disease: ready, set, slow.

Authors:  Steven M Hersch; H Diana Rosas
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

7.  Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.

Authors:  Brett D Dufour; Jodi L McBride
Journal:  Exp Neurol       Date:  2016-07-02       Impact factor: 5.330

8.  An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease.

Authors:  Karen Anderson; David Craufurd; Mary C Edmondson; Nathan Goodman; Mark Groves; Erik van Duijn; Daniel P van Kammen; Lavonne Goodman
Journal:  PLoS Curr       Date:  2011-09-20

9.  An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease.

Authors:  Mark Groves; Erik van Duijn; Karen Anderson; David Craufurd; Mary C Edmondson; Nathan Goodman; Daniel P van Kammen; Lavonne Goodman
Journal:  PLoS Curr       Date:  2011-08-30

Review 10.  Neuroprotective effects of psychotropic drugs in Huntington's disease.

Authors:  Edward C Lauterbach
Journal:  Int J Mol Sci       Date:  2013-11-15       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.